IRVINE, Calif.--(BUSINESS WIRE)--Cortex Pharmaceuticals, Inc. (AMEX: COR) will host a conference call on Wednesday, October 31, 2007 at 12:00 Noon EDT (9:00 AM PDT) to discuss the recently announced decision by the Division of Psychiatric Products (DPP) of the Food and Drug Administration to not permit the initiation of the proposed Phase IIb clinical study of CX717 in adult ADHD (attention deficit hyperactivity disorder), and its impact on the Company’s development programs.
